Aardvark Therapeutics, Inc. (AARD)
NASDAQ: AARD · Real-Time Price · USD
3.770
+0.130 (3.57%)
At close: Mar 31, 2026, 4:00 PM EDT
3.700
-0.070 (-1.86%)
Pre-market: Apr 1, 2026, 4:29 AM EDT

Aardvark Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22
82286---
Market Cap Growth
-58.47%----
Enterprise Value
-27.34176.3000
Last Close Price
3.7713.13---
PE Ratio
--4.48---
PB Ratio
0.771.29---
P/TBV Ratio
0.331.16---
P/FCF Ratio
--5.28---
P/OCF Ratio
--5.29---
EV/EBITDA Ratio
--2.81---
EV/EBIT Ratio
--2.81---
EV/FCF Ratio
--3.25---
Debt / Equity Ratio
-00.000.010.01
Debt / EBITDA Ratio
-0.01-0.01-0.03-0.02-0.02
Debt / FCF Ratio
-0.01-0.01-0.04-0.03-0.04
Net Debt / Equity Ratio
-0.49-0.49-19.780.280.57
Net Debt / EBITDA Ratio
1.751.753.201.331.39
Net Debt / FCF Ratio
2.022.024.011.692.72
Quick Ratio
10.4310.4314.957.2327.07
Current Ratio
10.6110.6115.057.5027.72
Return on Equity (ROE)
-32.63%-32.63%-29.51%-57.47%-84.88%
Return on Assets (ROA)
-64.44%-64.44%-51.76%-54.34%-67.81%
Return on Invested Capital (ROIC)
3392.37%3392.37%3104.22%2620.14%-7237.58%
Return on Capital Employed (ROCE)
-70.00%-70.00%-55.75%-58.58%-70.31%
Earnings Yield
-70.02%-22.32%---
FCF Yield
-65.98%-18.95%---
Buyback Yield / Dilution
-391.06%-391.06%-0.89%-1.78%-
Total Shareholder Return
-391.06%-391.06%-0.89%-1.78%-
Updated Mar 23, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q